 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Cortexyme, Inc. Nasdaq: CRTX, a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimers and other degenerative diseases, today announced that the independent Data Monitoring Committee DMC conducted a pre-planned interim analysis and recommended Cortexyme continue the Phase 23 GAIN Trial of atuzaginstat COR388 as planned to the 1-year endpoint. The interim analysis included approximately 300 patients who hav 